Halozyme Therapeutics (HALO) has drawn fresh attention after the stock reached a record high ahead of its upcoming earnings release, with investors watching how its patented drug delivery platform feeds into reported financials.

The recent record high comes after a strong run, with Halozyme Therapeutics posting a 90 day share price return of 30.82% and a 1 year total shareholder return of 38.62%. The 3 year total shareholder return of 94.35% points to momentum that has been building over a longer period.

If you are looking beyond Halozyme Therapeutics for more ideas in healthcare, this could be a useful moment to scan a wider group of 41 healthcare AI stocks

After this record run, Halozyme Therapeutics trades only modestly below the average analyst target, yet still at a heavy discount to one intrinsic value estimate. Where does a reasonable fair value anchor actually sit now?

Most Popular Narrative: 4.2% Undervalued

The most followed narrative currently points to a fair value of $86.89 for Halozyme Therapeutics compared with the last close at $83.28. This keeps attention squarely on the earnings and margin assumptions that underpin that gap.

The company's expanding network of global partnerships and the ramp-up of recently launched subcutaneous biologics (e.g., OCREVUS ZUNOVO, Opdivo Qvantig, Tecentriq Hybreza, RYBREVANT SC) provide a robust set of new and diversified royalty streams that are still early in their adoption curve. As these launches mature and penetration increases, especially in emerging and international markets, significant sequential revenue and EBITDA growth is anticipated.

Want to see what is baked into that $86.89 fair value for Halozyme Therapeutics? The narrative leans heavily on compounding royalties, rising margins and a leaner earnings multiple that still assumes solid growth.

Result: Fair Value of $86.89 (UNDERVALUED)

However, Halozyme Therapeutics also carries clear risks, including concentrated royalties in a few major partners and ongoing patent challenges that could reshape the long term earnings profile.

Another View on Halozyme Therapeutics Valuation

The narrative points to Halozyme Therapeutics trading at a discount to an $86.89 fair value, yet its P/E of 28.3x tells a different story. That ratio is higher than the US Biotechs industry at 16.9x and above a fair ratio of 20.1x, which implies less margin for error if earnings expectations are tested.

Next Steps

With mixed signals on valuation and sentiment around Halozyme Therapeutics, this is a good time to move quickly, review the full data set, and weigh both sides of the story using the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Halozyme Therapeutics?

Do not stop with Halozyme Therapeutics when there is a wider market of opportunities to review. Use the Simply Wall St screener to pressure test your next move.

• Spot potential mispricings early by scanning 49 high quality undervalued stocks that combine attractive pricing with underlying business quality.
• Prioritise resilience by reviewing 85 resilient stocks with low risk scores that score well on balance sheet strength and business stability.
• Get ahead of the crowd by filtering for screener containing 21 high quality undiscovered gems that show solid fundamentals before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.